Bradley J. Monk, MD, FACS, FACOG / Angeles Alvarez Secord, MD, MHSc - Enhancing Personalized Medicine in Advanced Ovarian Cancer: Expert Guidance on Integrating the Latest Updates on PARP Inhibitors and Novel Therapeutic Innovations Into Your Clinical Practice - a podcast by PVI, PeerView Institute for Medical Education

Go online to PeerView.com/CHG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For clinicians managing patients with advanced ovarian cancer, the use of poly (ADP-ribose) polymerase (PARP) inhibitors and new treatment modalities such as tumor treating fields (TTFields) represents an important opportunity to provide personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors. PARP inhibitors are also being actively researched in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Already approved in glioblastoma and mesothelioma, TTFields, a new modality that targets solid tumors via alternating electric fields, is paving the way for improved outcomes in a variety of cancers, including ovarian. In an engaging new educational activity, PeerView’s experts will present a series of MasterClasses featuring thorough reviews of the latest efficacy and safety data on current and emerging PARP inhibitor–based and novel therapeutic strategies for the treatment of patients with advanced ovarian cancer in a variety of settings. Drawing from their own practice, the experts will then provide guidance on using these agents—alone, in combination with other agents, and in the context of a clinical trial—with a focus on understanding the role of genetic testing, recognizing and managing adverse events, and working within a multidisciplinary care team to improve outcomes for patients. Upon completion of this accredited CE activity, participants should be better able to: Cite the mechanistic rationale and latest clinical evidence supporting the use of current and emerging PARP inhibitor–based strategies in patients with newly diagnosed and recurrent advanced ovarian cancer, Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel multimodal approaches into the management of patients with advanced ovarian cancer, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage adverse events related to the use of PARP inhibitors, particularly with long-term use such as in maintenance settings, in patients with ovarian cancer.

Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Further podcasts by PVI, PeerView Institute for Medical Education

Website of PVI, PeerView Institute for Medical Education